Anesthesia and analgesia
-
Anesthesia and analgesia · Aug 2001
Randomized Controlled Trial Clinical TrialThoracic epidural bupivacaine attenuates supraventricular tachyarrhythmias after pulmonary resection.
Supraventricular tachyarrhythmias after pulmonary surgery are well described. Some investigators suggest that tachyarrhythmias after thoracic operations may result from the relative sympathotonic status produced by injury to the cardiac parasympathetic nerves. We examined whether postoperative thoracic sympathetic blockade by thoracic epidural bupivacaine might reduce the tachyarrhythmias after pulmonary resection. Fifty patients with lung cancer were randomized to receive epidural bupivacaine (Group B) or epidural morphine (Group M). Patients in Group B were given 6 to 10 mL of 0.25% bupivacaine epidurally, followed by epidural infusion at 3 to 5 mL/h for 3 days, and patients in Group M were given 2 to 3 mg morphine epidurally, followed by morphine infusion at a rate of 0.2 mg/h. Tachyarrhythmias were diagnosed by using the continuous heart rate trend and arrhythmia trend with a central monitoring system. Postoperative analgesia was not statistically different between groups. However, the incidence of postoperative tachyarrhythmias in Group B was significantly less than in Group M (1 of 23 vs 7 of 25, P = 0.0497, Fisher's exact test). The continuous infusion of thoracic epidural bupivacaine can reduce supraventricular tachyarrhythmias compared with epidural morphine infusion, presumably because of attenuation of the sympathotonic status after pulmonary resection. ⋯ We examined whether postoperative thoracic sympathetic blockade by thoracic epidural bupivacaine after pulmonary resection might reduce the tachyarrhythmias that may result from the relative sympathotonic status produced by injury to the cardiac parasympathetic nerves. The continuous infusion of thoracic epidural bupivacaine was shown to reduce supraventricular tachyarrhythmias.
-
We determined the performance of the vaporizer of the ADU machine (Anesthesia Delivery Unit; Datex-Ohmeda, Helsinki, Finland). The effects of carrier gas composition (oxygen, oxygen/N(2)O mixture, and air) and fresh gas flow (0.2 to 10 L/min) on vaporizer performance were examined with variable concentrations of isoflurane, sevoflurane, and desflurane across the whole range of each vaporizer's output. In addition, the effects of sudden changes in fresh gas flow and carrier gas composition, back pressure, flushing, and tipping were assessed. Vaporizer output depended on fresh gas flow, carrier gas composition, dial settings, and the drug used. Vaporizer output remained within 10% of dial setting with fresh gas flows of 0.3-10 L/min for isoflurane, within 10% of dial setting with fresh gas flows of 0.5-5 L/min for sevoflurane, and within 13% of dial setting with fresh gas flows of 0.5 to 1 L/min for desflurane. Outside these fresh gas flow ranges, output deviated more. The effect of sudden changes in fresh gas flow or carrier gas composition, back pressure, flushing, and tipping was minimal. We conclude that the ADU vaporizer performs well under most clinical conditions. Despite a different design and the use of complex algorithms to improve accuracy, the same physical factors affecting the performance of conventional vaporizers also affect the ADU vaporizer. ⋯ The ADU vaporizer performs well under most clinical conditions. Despite a different design and the use of complex algorithms to improve accuracy, the same physical factors affecting the performance of conventional vaporizers also affect the ADU vaporizer.
-
Anesthesia and analgesia · Aug 2001
The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome.
Continuous neuromuscular blockade is often necessary in patients being treated for acute respiratory distress syndrome (ARDS) to optimize oxygenation. In this study, neuromuscular blockade (no response to two responses at the train-of-four stimulation at the orbicularis oculi muscle) was achieved in six patients with ARDS by a continuous infusion of cisatracurium. The plasma concentration of cisatracurium during the infusion averaged 1.00 (0.25-1.45) microg/mL, expressed as median (range). The clearance and half-life were 6.5 (3.3-7.6) mL. min(-1). kg(-1) and 25 (16-48) min, respectively. The laudanosine plasma concentrations were 0.70 (0.12-1.20) microg/mL. The pharmacokinetic variables of cisatracurium are similar to those of patients without organ failure undergoing elective surgery. Plasma laudanosine levels always remained well less that those associated with seizure activity in animal models. Long-term infusion of cisatracurium was not associated with any side effects. Cisatracurium is a suitable muscle relaxant when deep and continuous levels of muscle relaxation are required in patients treated for ARDS. ⋯ We studied the pharmacokinetics of cisatracurium in six patients treated for respiratory distress syndrome by continuous muscle relaxation. A deep degree of neuromuscular blockade corresponding to abolition of two responses at the orbicularis oculi to train-of-four stimulation was obtained in all patients. The pharmacokinetic variables observed in these severely ill patients were similar to those of anesthetized patients. No accumulation of laudanosine was seen. Cisatracurium appears to be suitable when continuous muscle relaxation is required in critically ill patients.
-
Anesthesia and analgesia · Aug 2001
A study of the paravertebral anatomy for ultrasound-guided posterior lumbar plexus block.
We investigated the feasibility of posterior paravertebral sonography as a basis for ultrasound-guided posterior lumbar plexus blockades. Posterior paravertebral sonography proved to be a reliable as well as accurate imaging procedure for visualization of the lumbar paravertebral region except the lumbar plexus.